BLZ-100 is the first Tumor Paint product candidate that is being developed for cancer surgery in multiple solid tumor types. BLZ-100 is a drug administered by IV injection that circulates within the body and “light ups” cancer cells. It consists of an Optide, which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range.
Preclinical utility of BLZ-100 has been demonstrated in a wide range of cancer types, including brain, breast, prostate, lung, colorectal, skin, and sarcomas. BLZ-100 is currently in multiple Phase 1 clinical trials.
Blaze Bioscience, in collaboration with the Fred Hutch, is developing a series of guided therapeutic product candidates based on Optides.
*In collaboration with Denali Therapeutics